Combination may offer a substitute to basal-bolus insulin in people with type 2 diabetes inadequately controlled with daily basal insulin.

"EASD 2024: A COMBINEd approach for better diabetes management" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

In July, Lilly rival Novo Nordisk failed to secure U.S. approval for its own once-weekly basal insulin icodec injection.